Načítá se...
Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis
The treatment of refractory ascites due to cirrhosis is a clinical challenge for hepatologists. Tolvaptan, a novel aquaporin modulator, was made available in Japan in 2013 for the treatment of patients with refractory ascites due to cirrhosis. Despite the potential of this drug, few reports are avai...
Uloženo v:
| Vydáno v: | Biomed Rep |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727763/ https://ncbi.nlm.nih.gov/pubmed/29250327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2017.1005 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|